Back
Neuphoria Therapeutics, Inc. 10K Form
Sell
44
NEUP
Neuphoria Therapeutics, Inc.
Last Price:
$3.87
Seasonality Move:
517.18%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
10K form not available
Receive NEUP News And Ratings
See the #1 stock for the next 7 days that we like better than NEUP
NEUP Financial Statistics
Sales & Book Value
| Annual Sales: | $15.6M |
|---|---|
| Cash Flow: | $-3.8M |
| Price / Cash Flow: | 609.79 |
| Annual Sales: | $5.31 |
| Price / Book: | 0.58 |
Profitability
| EPS (TTM): | 0.90350 |
|---|---|
| Net Income (TTM): | $-1.4M |
| Gross Margin: | $15M |
| Return on Equity: | -8.02% |
| Return on Assets: | -5.49% |
Neuphoria Therapeutics, Inc. Earnings Forecast
Key Neuphoria Therapeutics, Inc. Financial Ratios
-
The Gross Profit Margin over the past 27 years for NEUP is 95.76%.
-
The Selling, General & Administrative Expenses for NEUP have been equal to 49.67% of Gross Profit Margin.
-
The Research & Development expenses have been 57.54% of Revenue.
-
The Net Earning history of NEUP is -2.36% of Total Revenues.
-
Per Share Earnings over the last 27 years have been positive in 10 years.
Neuphoria Therapeutics, Inc. Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | NEUP |
| Website: | neuphoriatx.com |
Debt
| Debt-to-Equity Ratio: | 0.01 |
|---|---|
| Current Ratio: | 2.72 |
| Quick Ratio: | 2.68 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 0 |
NEUP Technical Analysis vs Fundamental Analysis
Sell
44
Neuphoria Therapeutics, Inc. (NEUP)
is a Sell
Is Neuphoria Therapeutics, Inc. a Buy or a Sell?
-
Neuphoria Therapeutics, Inc. stock is rated a SellThe current Neuphoria Therapeutics, Inc. [NEUP] share price is $3.89. The Score for NEUP is 44, which is 12% below its historic median score of 50, and infers higher risk than normal.